Healthcare technology company Medtronic has launched its PulseSelect™ Pulsed Field Ablation (PFA) system in India, introducing a new treatment option for patients suffering from atrial fibrillation (AFib), a common heart rhythm disorder that significantly increases the risk of stroke and heart failure.The company said AFib affects more than seven million people and its prevalence rises sharply with age. Despite the growing burden of the condition in India, awareness, diagnosis and treatment rates remain relatively low, with many patients experiencing mild or intermittent symptoms that often go unnoticed. Common symptoms include breathlessness, dizziness, palpitations, fatigue, chest discomfort and reduced exercise capacity.
The PulseSelect™ system uses short electrical pulses to treat abnormal heart rhythms, differing from conventional radiofrequency and cryoablation procedures that rely on heat or extreme cold. According to Medtronic, the technology is designed to minimise damage to surrounding tissues, reduce procedural risks and support faster recovery. Its safety and effectiveness have been demonstrated through Investigational Device Exemption clinical trials.ChandrashekharJaiman, Senior Director, Cardiovascular Surgery and Electrophysiology Therapies at Medtronic India, said the introduction of the technology expands treatment options for physicians and supports efforts to address the growing burden of stroke and cardiovascular diseases linked to AFib in the country.
Healthcare experts and medical technology stakeholders in Kolkata view the launch as a positive development for eastern India’s cardiac care ecosystem. With the city emerging as a major healthcare hub serving patients from West Bengal and neighbouring states, advanced electrophysiology technologies such as PulseSelect™ could strengthen access to specialisedAFib treatment, support hospitals in adopting next-generation cardiac procedures and contribute to improved patient outcomes across the region.